1. Home
  2. FISV vs INSM Comparison

FISV vs INSM Comparison

Compare FISV & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fiserv Inc.

FISV

Fiserv Inc.

N/A

Current Price

$56.00

Market Cap

34.1B

Sector

Real Estate

ML Signal

N/A

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$154.43

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FISV
INSM
Founded
1984
1988
Country
United States
United States
Employees
38000
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1B
30.1B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
FISV
INSM
Price
$56.00
$154.43
Analyst Decision
Buy
Strong Buy
Analyst Count
28
24
Target Price
$146.17
$200.48
AVG Volume (30 Days)
6.1M
2.3M
Earning Date
04-24-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$177.03
Revenue Next Year
$3.92
$66.55
P/E Ratio
$9.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$52.91
$63.81
52 Week High
$70.41
$212.75

Technical Indicators

Market Signals
Indicator
FISV
INSM
Relative Strength Index (RSI) 43.87 51.40
Support Level $52.91 $137.93
Resistance Level $68.35 $167.01
Average True Range (ATR) 1.78 6.54
MACD 0.25 1.09
Stochastic Oscillator 55.18 59.43

Price Performance

Historical Comparison
FISV
INSM

About FISV Fiserv Inc.

Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: